# Earli

> Synthetic biopsy biotech forcing tumors to produce detectable biomarkers for ultra-early cancer localization.

## Why it is interesting

a16z Bio led seed; Khosla led Series A with Menlo — Stanford-licensed platform now advancing toward clinic.

## Profile

- **Stage:** series-a
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (Jan 2021): $40M led by Khosla; a16z and Menlo participated (BusinessWire)
- Seed (2018): $19.5M led by a16z Bio + Health and Marc Benioff; Menlo joined (BusinessWire)

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/khosla-ventures
- https://venturecapitaltracker.com/fund/menlo-ventures

---
Source: https://venturecapitaltracker.com/startup/earli